
Malaysia records first Covid death of 2025
Malaysia saw its first Covid death of 2025 earlier this month, health authorities said.
The health ministry noted that this was the first Covid fatality since 26 May last year.
The deceased had heart disease and diabetes and hadn't taken a second booster shot.
'This marks a significant decline compared to 57 Covid deaths reported in 2024, with the last fatality recorded on May 26 last year,' the ministry said in a statement on Thursday.
From January to 15 June this year, Malaysia recorded 21,738 cumulative Covid cases, with the weekly average holding at about 900, The Rakyat Post reported.
The ministry reported a sharp 68 per cent week-on-week increase with 3,379 cases from 8 to 15 June compared to 2,011 the week prior.
Despite the rise, the ministry stressed the national situation remained stable and well below the alert threshold.
At least six individuals with underlying health conditions had been admitted to ICU. 'All cases were closely monitored with care, with all patients discharged from the ICUs. Four were allowed to return home, with two transferred to normal wards,' the ministry said.
The new Nimbus Covid strain (NB.1.8.1) is rapidly spreading around the world and is being closely monitored by the World Health Organisation. This strain is linked to a rise in infections in several parts of Asia, including India, Hong Kong, Thailand, and Singapore.
First recognised in January 2025, NB.1.8.1, an omicron variant, is now the dominant variant in China and Hong Kong. It has also spread to the US and Australia.
' SARS-CoV-2 continues to evolve, and between January and May 2025, there were shifts in global SARS-CoV-2 variant dynamics,' a WHO spokesperson said earlier.
'At the beginning of the year, the most prevalent variant tracked by WHO at the global level was XEC, followed by KP.3.1.1. In February, circulation of XEC began to decline while that of LP.8.1 increased, with the latter becoming the most detected variant in mid-March. Since mid-April, the circulation of LP.8.1 has been slightly declining as NB.1.8.1 is increasingly being detected.'
By late April, NB.1.8.1 comprised about 10.7 per cent of submitted sequences globally, according to the WHO, up from just 2.5 per cent a month before.
The WHO has designated Nimbus as a Variant Under Monitoring. Preliminary data suggests that Nimbus spreads more rapidly than earlier variants.
Reported symptoms commonly include a sharp, razor-like sore throat, fatigue, mild cough, fever, muscle aches, and nasal congestion.
However, the public health risk posed by this variant is evaluated as low at the global level. 'Despite a concurrent increase in cases and hospitalisations in some countries where NB.1.8.1 is widespread, current data don't indicate that this variant leads to more severe illness than other variants in circulation,' the WHO said.
Although it may not be particularly severe, Nimbus may infect people more easily than earlier variants. There's some evidence that the variant binds more tightly to human cells.
The ministry of health urged all Malaysians to stay protected by adhering to the recommended vaccination schedules outlined in the National Immunisation Programme.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
2 hours ago
- The Independent
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.


The Independent
4 hours ago
- The Independent
Weight loss pill set to rival injections after promising studies
A new daily weight loss pill has shown promising results in initial studies. Researchers say amycretin, which can be offered by injection or tablet, helped patients lose a significant amount of weight in the first trials. Those who received higher doses of amycretin as a weekly jab lost 24.3 per cent of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks. While weight loss jabs have been hailed as transformative by NHS leaders, injections come with additional work for over-stretched health services, so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs of improving blood sugar levels. Side effects included nausea and vomiting, and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association 's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.


The Independent
4 hours ago
- The Independent
Popular children's cough medicine recalled over potentially deadly bacterial infection risk
A popular cough medicine for children has been recalled over a risk of bacterial infection that can be deadly. Little Remedies Honey Cough Syrup was recalled Tuesday over the 'presence' of Bacillus cereus, a type of bacteria that can cause two types of foodborne illnesses, and because of 'loss of shelf-stability,' according to a notice from the medicine makers, Medtech Products Inc. The recall describes the symptoms associated with both foodborne illnesses. One can cause nausea, vomiting and stomach cramps starting one to six hours after consuming contaminated food. The second illness can cause stomach cramps and diarrhea starting 8 to 16 hours after exposure. 'Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death,' the recall notice warned. No serious adverse effects have been reported as of the date of the recall. The recalled cough syrup was sold by retailers throughout the country and online from December 14, 2022, to June 4, 2025. Consumers with the recalled medicine are advised to stop using it immediately and contact their doctor if they experience any symptoms that may be related to the product. The company is also offering a refund of the product.